528
Participants
Start Date
June 14, 2021
Primary Completion Date
December 8, 2023
Study Completion Date
January 31, 2024
artemether-lumefantrine (ALN)
Assessing the efficacy on current 1st line antimalarial, and an alternative 1st line or 2nd line medicine
dihydroartemisinin-piperaquine (DHA-PPQ)
dihydroartemisinin-piperaquine (DHA-PPQ)
Bugarama health center, Bugarama
Masaka health center, Masaka
Rukara health center, Rukara
Ministry of Health, Rwanda
OTHER_GOV
Centers for Disease Control and Prevention
FED
United States Agency for International Development (USAID)
FED
Jhpiego
OTHER